[1]Patent:WO2008/22281,2008,A1.Locationinpatent:Page/Pagecolumn59
[2]JournalofMedicinalChemistry,1997,vol.40,p.4378-4385
124-40-3
199666-03-0
[1]Patent:WO2008/22281,2008,A1.Locationinpatent:Page/Pagecolumn59-60
[1]Patent:WO2008/22281,2008,A1.Locationinpatent:Page/Pagecolumn61-62
[1]Patent:WO2008/22281,2008,A1.Locationinpatent:Page/Pagecolumn66-67
[1]Patent:US5877193,1999,A
Title: The antioxidant role of xanthurenic acid in the Aedes aegypti midgut during digestion of a blood meal.
Journal: PloS one 20120101
Title: Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
Journal: Cell 20110610
Title: Inhibition of the kynurenine-NAD+ pathway leads to energy failure and exacerbates apoptosis in pneumococcal meningitis.
Journal: Journal of neuropathology and experimental neurology 20101101
Title: Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Journal: Neuropharmacology 20100101
Title: Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Journal: Journal of molecular neuroscience : MN 20090601
Title: Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis.
Journal: Brain : a journal of neurology 20090501
Title: Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
Journal: International journal for parasitology 20090201
Title: Kynurenine pathway metabolites in humans: disease and healthy States.
Journal: International journal of tryptophan research : IJTR 20090101
Title: Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant.
Journal: European journal of pharmacology 20080531
Title: Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Journal: Behavioural brain research 20080125
Title: Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Journal: Movement disorders : official journal of the Movement Disorder Society 20050701
Title: Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus.
Journal: Neuropharmacology 20050501
Title: The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia.
Journal: European journal of pharmacology 20030930
Title: Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
Journal: Journal of neurochemistry 20020901
Title: Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.
Journal: Neuroscience 20010101
Title: S Röver, et al. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem. 1997 Dec 19;40(26):4378-85.
Title: Melanie Hamann, et al. Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant. Eur J Pharmacol. 2008 May 31;586(1-3):156-9.
Title: AlbertoChiarugi, et al. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl) thiazol-2yl-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology. Volume 38, Issue 8, August 1999, Pages 1225-1233.
